Chronos-PD is Grifols’ latest research initiative in over a century of plasma science innovation. It has the potential to revolutionize management of Parkinson’s disease (PD) and many other conditions. Using our plasma repository, one of the world’s largest with over 100 million samples collected over nearly 15 years, we study past samples to detect early biological signals in plasma proteins that may indicate the earliest signs of disease even before symptoms appear. This research could lead to new ways to diagnose and treat the condition.

 

Currently, our focus is on Parkinson’s disease. But our plasma collection potentially holds the key to studying and developing therapies for many more conditions in the future.

Video Player is loading.
Current Time 0:00
Duration 1:05
Loaded: 0%
Stream Type LIVE
Remaining Time 1:05
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected

    Seeking Early Biological Signals of Disease

    Grifols has been conserving plasma samples for nearly 15 years. Researchers at our subsidiary, Alkahest, are now studying these biospecimens to identify early biological signals – called biomarkers – of diseases in plasma proteins.

    Proprietary plasma collection

    Grifols’ repository of plasma samples is one of the world's largest, with more than 100 million samples. When linked to real-world data they cover thousands of different diseases and disease states and likely have protein changes in plasma that show early signs of disease.

    Using AI and proteomics, Alkahest data scientists are analyzing real-world data in diagnostic and therapeutic drug discovery to study thousands of proteins present in these plasma samples. This innovative approach could accelerate the discovery of new diagnostic tools and therapeutics and will potentially predict which patients might have an increased chance of developing certain diseases in future.

    Chronos-PD

    Grifols has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to identify plasma-based biomarkers that could indicate a person’s likelihood of developing Parkinson’s disease (PD) many years before clinical diagnosis. The funding will support a pilot study to analyze longitudinal plasma samples collected over a period of up to 10 years, enabling researchers to track how distinct plasma proteins evolve over time in people with PD, which could help establish an early-warning system for the emergence of the disease.


    Even after decades of research and treatment advancements, understanding what causes the disease remains limited. Finding early detection biomarkers is urgently needed to improve treatments for Parkinson’s disease and halt or alter its progression.

    The Platform’s Expansive Potential

    Grifols’ vision is that the platform will continue to grow in terms of knowledge, partnerships and its ability to help society advance in fighting some of the world’s most pressing public health challenges.

    Only a company like Grifols, with over a century of leadership in plasma science and innovation, has the expertise and resources to lead a project of this scale. Chronos has the potential to transform diagnostics and treatments for Parkinson’s and potentially many other diseases, improving outcomes and quality of life for patients worldwide.

    Researching neurodegenerative diseases